NICOLE KEEDY: Open Payments
NPI 1194255612 · LINCOLN, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,268 in 79 payments from 17 companies in 2025. Trend: 2023 $1,305 · 2024 $1,142 · 2025 $1,268
Food & beverage: $1,268
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 28 | $377 |
| ABBVIE INC. | 9 | $185 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $181 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 4 | $73 |
| Boston Scientific Corporation | 1 | $67 |
| Phathom Pharmaceuticals, Inc. | 8 | $66 |
| Gilead Sciences, Inc. | 2 | $58 |
| Celltrion USA Inc. | 3 | $44 |
| GENZYME CORPORATION | 2 | $39 |
| Lilly USA, LLC | 2 | $37 |
Products named: TREMFYA, ENTYVIO, LINZESS, XIFAXAN, OverStitch Endoscopic Suturing System, VOQUEZNA, DUPIXENT, VEGZELMA.
Industry payments across NE — which companies pay providers there.
